RIPK1 and tuberculosis: Based on the above studies, LncRNA NR_003508 small interfering agent, may be used in the clinical treatment of tuberculosis to inhibit the expression of RIPK1 through miR-346-3p, thereby inhibiting programmed necrosis in a certain range and controlling the spread of Mtb in vivo, which might be a novel therapeutic target for tuberculosis.